TLR4 and steatosis: In previous study, decreased LPS production from the gut by OCA treatment activated TLR-4 and TLR-9, thus promoting inflammation, steatosis, and fibrosis, which might have contributed to reduced liver fibrosis (Lichtman et al., 1990).